Last reviewed · How we verify
Feximac — Competitive Intelligence Brief
marketed
bufexamac
Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Feximac (BUFEXAMAC).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Feximac TARGET | BUFEXAMAC | marketed | bufexamac | Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (bufexamac class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Feximac CI watch — RSS
- Feximac CI watch — Atom
- Feximac CI watch — JSON
- Feximac alone — RSS
- Whole bufexamac class — RSS
Cite this brief
Drug Landscape (2026). Feximac — Competitive Intelligence Brief. https://druglandscape.com/ci/bufexamac. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab